The putative beneficial effects of supplemental Lutein (L) and Zeaxanthin (Z) with co-antioxidants in patients with age-related maculopathy: A pilot short term randomised controlled clinical trial of antioxidant supplementation

ISRCTN ISRCTN94557601
DOI https://doi.org/10.1186/ISRCTN94557601
Secondary identifying numbers DMP628.1.03
Submission date
01/07/2005
Registration date
25/07/2005
Last edited
12/12/2012
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Usha Chakravarthy
Scientific

Ophthalmology and Vision Science
Institute of Clinical Science
Queen's Univerisity of Belfast
Royal Victoria Hospital
Belfast
BT12 6BA
United Kingdom

Phone +44 (0)28 90633955
Email u.chakravarthy@qub.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typePrevention
Scientific title
Study acronymCARMA
Study objectivesSubjects aged 50 years and older with evidence of early ARM in both eyes or advanced AMD in one eye.

The primary hypothesis is that progression from early ARM to late AMD may be delayed or prevented through supplementation with key antioxidants (vitamins, minerals and carotenoids) which are either known to be present in high concentrations in healthy neural retina/retinal pigment epithelium (RPE)/choroidal interface or are free radical scavengers and thus have potential protective roles in minimisation of oxidative stress.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedAge-related maculopathy
InterventionDaily oral administration of supplement - Lutein + Zeaxanthin + Vitamin E + C + Zn/Cu tablet per day (to be known as CARMA Preparation)
Control: Placebo
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Lutein, Zeaxanthin, co-antioxidants
Primary outcome measureThe primary outcome will be retinal acuity in the study eye at 12 months of supplementation. The level of significance for changes will be set at 0.05.
Secondary outcome measures1. Change in distance visual acuity (DVA) in treatment and control groups at 12 months. Similar to the primary outcome the level of significance for changes will be set at 0.05.
2. Progression of ARM based on detailed grading of stereo colour fundus images. Progression is defined as a change of at least one step in the level of severity as gauged by the appearance or an increase in (a) drusen (size, frequency and extent), (b) focal hyper or hypopigmentation (area).
3. In vivo macular carotenoid signal strength.
4. Serum markers Vitamin C, lipid soluble vitamins, cholesterol.

Data from all patients who continued supplementation for more than 12 months will be collected and analysed in order get as much information as possible regarding the changes of visual function during the duration of the study. These additional data will be analysed independently from the primary and secondary outcomes at 12 months of supplementation.
Overall study start date01/06/2004
Completion date01/04/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants360
Key inclusion criteria1. Patient must be willing to give written informed consent, make the required study visits, and follow instructions
2. Patient must be at least 50 years of age
3. Patients may be of any race or sex
4. Two groups of ARM patients may be included
Group 1: If there is choroidal neovascularisation (CNV) or geographic atrophy (GA) in one eye, any level of ARM is permissible in the fellow eye provided visual acuity (VA) is equal to or better than logarithm of the minimum angle of resolution (logMAR) 0.3
Group 2: Clinical diagnosis of severe early ARM in at least one eye.
≥20 soft distinct or soft indistinct drusen or if fewer that 20 soft drusen, focal hyper pigmentation must be present.
Visual acuity greater than or equal to 6/12 or 0.3 logMAR in the study eye (which may be both eyes).
Key exclusion criteria1. Any retinal laser therapy in the study eye
2. In Group 1 there should be no visible choroidal neovascularisation or geographic atrophy
3. History of any unstable medical condition or life threatening conditions, for example, cancer or renal failure, that would preclude scheduled study visits or completion of the study
4. History of ophthalmic disease in the study eye (other than ARM) that would compromise the visual acuity of the study eye
5. Patients currently on supplements containing the antioxidants C, E, Zn, L and Z will be asked to discontinue them and may, after a washout period of three months, be eligible for randomisation into the study
6. History of malabsorption
7. History of psychiatric disorder, which may interfere with compliance in taking study medication or attendance for study visits
8. Patients with known allergy against one of the active ingredients or the other excipients in the study medications
Date of first enrolment01/06/2004
Date of final enrolment01/04/2007

Locations

Countries of recruitment

  • Northern Ireland
  • United Kingdom

Study participating centre

Ophthalmology and Vision Science
Belfast
BT12 6BA
United Kingdom

Sponsor information

Dr. Mann Pharma GmbH, Bausch & Lomb Group (Germany)
Industry

Brunsbuetteler damm 165
Berlin
13581
Germany

Phone +49 (0)30 33093329
Email annette.schappach@bausch.com
ROR logo "ROR" https://ror.org/049ncrn81

Funders

Funder type

Industry

Dr Mann Pharma, Bausch and Lomb and Chauvin Group Berlin, Germany

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Other publications design and methods 01/11/2008 Yes No
Results article results 01/09/2011 Yes No
Results article results 01/03/2013 Yes No